Hyderabad News Desk

Neuro Myelitis Optica Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Alexion Pharmaceuticals, Horizon Pharmaceuticals

 Breaking News
  • No posts were found

Neuro Myelitis Optica Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Alexion Pharmaceuticals, Horizon Pharmaceuticals

October 17
09:27 2023
Neuro Myelitis Optica Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Alexion Pharmaceuticals, Horizon Pharmaceuticals
DelveInsight Business Research LLP
DelveInsight’s “Neuromyelitis Optica Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Neuromyelitis Optica, historical and forecasted epidemiology as well as the Neuromyelitis Optica market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Neuromyelitis Optica Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Neuromyelitis Optica, historical and forecasted epidemiology as well as the Neuromyelitis Optica market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Neuro Myelitis Optica Key Highlights 

  • Key Companies working in the Neuro Myelitis Optica market include Alexion Pharmaceuticals, Horizon Pharmaceuticals, and many others   

  • Key Therapies included in the Neuro Myelitis Optica market include Tocilizumab,  Orelabrutinib,  Rituximab, and many others 

Neuro Myelitis Optica Overview

Neuromyelitis optica is a central nervous system disorder that causes inflammation in the nerves of the eye and the spinal cord. NMO is also called neuromyelitis optica spectrum disorder (NMOSD) and Devic disease. It occurs when the body’s immune system reacts against its own cells.

The disorder may appear after an infection. Or it can be associated with another autoimmune condition. Irregular antibodies bind to proteins in the central nervous system and cause damage.

Neuro Myelitis Optica Epidemiology Insights

  • The prevalence of Neuro Myelitis Optica is approximately 1-10 per 100,000 individuals and seems to be similar worldwide, although somewhat higher rates have been reported in countries with a higher proportion of individuals of African ancestry.

  • The prevalence range of NMOSD is ~0.5–4/100,000 and may be up to 10/100,000 in certain racial groups. Nevertheless, this prevalence range is rather small relative to that of MS, which ranges from 1–2/100,000 in the equatorial region, to 150–200/100,000 in Canada and the northern part of Europe.

 

Click here to learn more about the Neuro Myelitis Optica Market Landscape

 The Report Covers the Neuro Myelitis Optica Epidemiology Segmented by:

  • Neuro Myelitis Optica prevalent cases 

  • Neuro Myelitis Optica incident cases 

  • Neuro Myelitis Optica treatment cases 

  • Neuro Myelitis Optica diagnosed cases 

 

Neuro Myelitis Optica Market Outlook 

The Neuromyelitis Optica market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Neuromyelitis Optica market trends by analyzing the impact of current Neuromyelitis Optica therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Neuromyelitis Optica market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Neuromyelitis Optica market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Neuromyelitis Optica market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Neuro Myelitis Optica Market 

  • Alexion Pharmaceuticals, 

  • Horizon Pharmaceuticals, 

And many others 

 

Neuro Myelitis Optica Therapies Covered and Analyzed in the Report

  •  Tocilizumab,  

  • Orelabrutinib

And many others 

 

Learn more about the Key Companies and Emerging Therapies in the Neuro Myelitis Optica Market

Table of Contents 

  1.  Key Insights 

  2.  Neuro Myelitis Optica Introduction 

  3.  Executive Summary of Neuro Myelitis Optica         

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  Neuro Myelitis Optica Emerging Therapies

  7.  Neuro Myelitis Optica Market Outlook

  8.  Market Access and Reimbursement of Therapies

  9.  Market Drivers 

  10.  Market Barriers 

  11.  Appendix

  12.  Report Methodology

  13.  DelveInsight Capabilities

  14.  Disclaimer

Learn about the detailed offerings of the report @ Neuro Myelitis Optica Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Categories